Fig. 4
From: Exploiting RIG-I-like receptor pathway for cancer immunotherapy
Intratumoral and intravenous delivery of RLR-activating RNA. In vivo jetPEI, liposome, injectable hydrogel and extracellular vesicles can serve as the vehicles for intratumoral delivery of RLR-activating RNA. Systemic delivery of RLR-activating RNA can be achieved by intravenous injection of nanoparticles such as carboxylic acid-terminated poly(lactic-co-glycolic acid) (PLGA), lipid–calcium–phosphate (LCP) and lipid nanoparticles (LNP). In addition, CAR-T cells can deliver and release the RLR-activating RNA